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Abstract
Background: Chronic low back pain (LBP) is the leading cause of pain and disability, resulting in a major
socioeconomic impact. The Cochrane Review which examined the effect of spinal manipulative therapy (SMT) for
chronic LBP concluded that SMT is moderately effective, but was based on conventional meta-analysis of aggregate
data. The use of individual participant data (IPD) from trials allows for a more precise estimate of the treatment
effect and has the potential to identify moderators and/or mediators. The aim is (1) to assess the overall treatment
effect of SMT for primary and secondary outcomes in adults with chronic LBP, (2) to determine possible moderation
of baseline characteristics on treatment effect, (3) to identify characteristics of intervention (e.g., manipulation/
mobilization) that influence the treatment effect, and (4) to identify mediators of treatment effects.
Methods: All trials included in the Cochrane Review on SMT for chronic LBP will be included which were published after
the year 2000, and the search will be updated. No restrictions will be placed on the type of comparison or size of the
study. Primary outcomes are pain intensity and physical functioning. A dataset will be compiled consisting of individual
trials and variables included according to a predefined coding scheme. Variables to be included are descriptive of
characteristics of the study, treatment, comparison, participant characteristics, and outcomes at all follow-up periods. A
one-stage approach with a mixed model technique based on the intention-to-treat principle will be used for the analysis.
Subsequent analyses will focus on treatment effect moderators and mediators.
Discussion: We will analyze IPD for LBP trials in which SMT is one of the interventions. IPD meta-analysis has been shown
to be more reliable and valid than aggregate data meta-analysis, although this difference might also be attributed to the
number of studies that can be used or the amount of data that can be utilized. Therefore, this project may identify
important gaps in our knowledge with respect to prognostic factors of treatment effects.
Systematic review registration:: PROSPERO CRD42015025714
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Introduction
Background
Low back pain (LBP) is one of the leading causes of pain
and disability and has a major socioeconomic impact [1,
2]. The majority of the costs associated with LBP are
generated by participants whose condition proceeds to
chronicity. There is evidence that the costs of chronic
LBP are rising, while the prevalence remains the same
[3]. Spinal manipulative therapy (SMT) is a commonly
used strategy to treat chronic LBP and is one of the sev-
eral interventions which evidence suggests is moderately
effective [4].
SMT is defined as including both spinal manipulation
and mobilization and is the experimental intervention
examined in this review. Unless otherwise indicated,
SMT refers to both of these “hands-on” treatments [5,
6]. Mobilizations use low-grade velocity, small or large
amplitude passive movement techniques within the par-
ticipant’s range of motion and control. Manipulation, on
the other hand, uses a high-velocity impulse or thrust
applied to a synovial joint over a short amplitude at or
near the end of the passive or physiologic range of mo-
tion, which is often accompanied by an audible “crack”
[7]. The cracking sound is caused by a cavitation of the
joint, which is a term used to describe the formation
and activity of bubbles within the fluid [8].
Many hypotheses exist regarding the mechanism of ac-
tion for spinal manipulation and mobilization [9–11],
and some have postulated that given their theoretically
different mechanisms of action, mobilization and ma-
nipulation should be assessed as separate entities [8].
The modes of action might be roughly divided into
mechanical and neurophysiologic. The mechanical ap-
proach proposes that SMT acts on a manipulable lesion
(often called the functional spinal lesion or subluxation)
to reduce internal mechanical stresses resulting in re-
duced symptoms [12]. However, given the non-
nociceptive behavior of chronic LBP, a purely mechanical
theory alone cannot explain clinical improvement [8].
The neurophysiologic mechanism proposes that SMT
impacts the primary afferent neurons from the para-
spinal tissues, the motor control system, and pain pro-
cessing [10], although the actual mechanism remains
debatable [8, 9].
In back pain research on the effect of SMT, identifica-
tion of relevant patient subgroups is an important goal
[13, 14]. For clinicians, a source of frustration in back
pain research has been the lumping of patients together
as “non-specific LBP” even though there is an underlying
presumption that relevant subgroups of individuals with
chronic LBP exist. There has been extensive inter-
national attention in this area, which aims to identify
patient-level characteristics that modify treatment effect
[15]. In addition to effect modification, it is important to
identify and subsequently target critical intervention
components (that is, mediators of intervention effect).
Mediators are causal links between the intervention and
the outcome and identify how an intervention might
achieve its effects. However, evidence on this topic is
scarce or lacking altogether. Still this presumption of
relevant subgroups may be one of the reasons that re-
sults from studies so far have, at best, only shown mod-
est average treatment effects. The resulting lack of this
knowledge may hamper clinical decision-making in LBP
by clinicians.
Another challenge in the investigation of treatments
for LBP is to adequately assess the exact content and
complexity of clinical management. Commonly, SMT
are delivered as a “programme of care” rather than a
specific individual treatment. We observed this in a pre-
vious work; SMT is often provided in combination with
advices and/or exercises and it is difficult to separate the
effect of the different components. Also, SMT interven-
tion encompasses a heterogeneous group of interven-
tions including different types of treatment (e.g., high-
velocity low-amplitude (HVLA) manipulation versus
low-velocity passive or resisted movement mobilization)
[4]. Furthermore, most LBP trials are underpowered to
detect modifiers of treatment response [16].
It is necessary to identify relevant differences in treat-
ment and patient subgroups to get a better understand-
ing of the “best” strategies for SMT in chronic LBP
patients. This can potentially lead to better informed
clinical practice.
Individual participant data meta-analysis
In a traditional systematic review, published data are
summarized in meta-analyses resulting in differences in
mean treatment effect. This standard approach of pool-
ing data increases statistical power and allows the effect
sizes to be estimated with greater precision.
However, meta-analyses that collect published aggre-
gate study data and pool study results have limitations.
For example, subgroup data are typically not presented
and the power to detect true effect modifiers is low [17].
Therefore, as some argue, meta-analyses that, bring to-
gether this heterogeneous information, have limited rele-
vance in the management of individual patients in
clinical practice [18].
An alternative approach to evidence synthesis is meta-
analysis of individual participant data meta-analysis
(IPD). IPD meta-analysis potentially allows for explor-
ation of treatment effects and its interactions with indi-
vidual patient characteristics.
In IPD meta-analysis, the individual-level data from
each randomized clinical trial (RCT) is obtained, so IPD
can be considered the original source material. There
are several advantages of IPD meta-analysis. Firstly, IPD
de Zoete et al. Systematic Reviews  (2017) 6:21 Page 2 of 11
allows one to standardize analyses across studies and
directly derive the information desired, independent of
significance or how it was reported in the original study
[17, 19]. Secondly, IPD may also include, more follow-
up data, more participants, and more outcomes com-
pared with aggregate meta-analysis as more data may be
available to be pooled [17, 19]. Thirdly, additional ana-
lyses can be carried out to explore heterogeneity [17,
19]. Finally, a complete master database can be main-
tained for future collaborative initiatives as long as study
authors are in agreement.
In addition to the many advantages of IPD, there
are challenges to the use of IPD. One of the chal-
lenges of IPD is retrieving the datasets of all relevant
RCTs. Not all datasets can be collected, because of
several reasons. For example, authors, who published
an RCT several years ago, may not be easily located,
datasets may have been lost, authors are not willing
to share their data, or authors are not allowed to
share their data because of ethical reasons. In
addition to collection of the data, the generation of
a consistent data format across studies is very time
consuming and may not be possible due to differ-
ences in measurement of domains across studies.
Furthermore, IPD analyses require advanced statis-
tical expertise.
Despite all these challenges, the advantages of using
an IPD meta-analysis can be considerable both statisti-
cally and clinically compared to a meta-analysis of aggre-
gate data which is why IPD meta-analyses are
increasingly being applied [17].
On average, SMT for people with chronic LBP is mod-
erately effective, SMT can relieve LBP in some patients
but it does not seem to be effective for everyone. This
differential response can be caused by moderators. Po-
tential moderators, which have been identified in the lit-
erature, are gender, age, duration of back pain,
psychosocial factors, and treatment preference or expec-
tations [20]. In addition, in the literature there is little
information about mediators that influence SMT for
LBP. Aggregate meta-analysis is not well suited to exam-
ine mediation effects. This IPD may help to identify po-
tential moderators and/or mediators of patients who
improve or who fail to improve when treated with SMT,
which can lead to predict improved outcomes and re-
duction in costs.
Study objectives
The objectives of this study are as follows:
 To perform an IPD meta-analysis to assess the treat-
ment effect of SMT compared to any other treat-
ment for primary outcomes (pain and physical
functioning) and secondary outcomes (perceived
recovery, return-to-work or absenteeism, health-
related quality of life, satisfaction with treatment,
and reduction in frequency of analgesic use) at the
short and long term follow-up periods in adults with
chronic LBP.
 To explore potential SMT treatment effect
moderation of individual patient characteristics
measured at baseline according to prespecified
theoretical framework (Tables 1 and 2).We will
consider age, gender, duration of low back pain,
psychosocial factors, and treatment preference/
expectation) as candidate treatment effect moderators,
while the exploratory moderators will only be used as a
guide for future research (Tables 1 and 2).
 To identify characteristics of the SMT interventions
(e.g., manipulation/mobilization) that influence the
treatment effect.
 To identify mediators of treatment effects (e.g.,
physical functioning may mediate the association
between SMT and return-to-work). All mediators
are exploratory and therefore only be used as a guide
for future research.
Methods
The protocol was developed according to the Preferred
Reporting Items of Systematic Reviews and Meta-
Analyses Protocol (PRISMA-P) guidelines [21], and the
protocol has been registered on PROSPERO database
(Ref:CRD42015025714). The PRISMA-P checklist is in-
cluded as an additional file (see additional file 1).
Criteria for including studies for this study
Types of studies and types of participants
Only RCTs will be included which evaluate the effects of
SMT in adults (≥18 years of age) with an identifiable
group of patient with chronic (≥12 weeks duration) non-
specific LBP (alone or with leg pain) from primary or
secondary care. Studies, which compare the effects of
SMT as part of a multi-modal treatment, will be in-
cluded as long as the effects of SMT can be determined,
for example, SMT plus another intervention versus
the same intervention alone. We will extract only the
data on the patients with chronic LBP from RCTs
with mixed acute and chronic LBP population, if feas-
ible (we included only studies where the duration of
LBP is more than 12 weeks of low-back pain in more
than 50% of the population).
Studies using an inadequate randomization procedure
(e.g., alternate allocation, allocation based on birth date)
will be excluded as well as studies including individuals
with LBP caused by specific pathologies (e.g., tumor,
fracture). Studies including only patients with LBP and
other conditions such as pregnancy or post-operative pa-
tients will also be excluded.
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We will obtain only the studies published in 2000 or
later, as we expect to receive more data from recent
studies than older studies because it is difficult to trace
authors of older studies, and there is a high probability
that the data from older studies has been lost or
destroyed. However, this is not likely to negatively influ-
ence our analysis because the quality of studies has im-
proved over time and therefore, we expect that these
newer studies will yield more valid answers to our ques-
tions (45)
Types of interventions
Experimental intervention
The interventions examined in this review include both
spinal manipulation and mobilization for chronic LBP.
Unless otherwise indicated, SMT refers to both “hands-
on” treatments.
Types of comparison
Studies will be included if the study design used suggests
that the observed differences are due to the unique con-
tribution of SMT. This excludes studies with a multi-
modal treatment as one of the interventions (e.g., stand-
ard physician care + spinal manipulation + exercise ther-
apy) and a different type of intervention or only one
intervention from the multi-modal therapy as the com-
parison (e.g., standard physician care alone), thus ren-
dering it impossible to decipher the effect of SMT.
However, studies comparing SMT in addition to another
intervention compared to that same intervention alone
will be included. Comparison therapies will be combined
into the following main clusters based on the Cochrane
Review [4]:
(1)SMT versus inert interventions
(2)SMT versus sham SMT
(3)SMT versus all other interventions
(4)SMT in addition to any intervention versus that
intervention alone
Inert interventions included, for example, detuned dia-
thermy and detuned ultrasound. “All other interven-
tions” included both presumed effective and ineffective
Table 1 Overview of outcomes extracted for IDP analyses and
the role of the variable in moderator analysis
Domain Assessment instruments/
measurements scales
Exploratory/confirmatory
moderator analysis
Primary outcomes
Pain e.g., Visual Analog Scale
Numerical Rating Scale,
Aberdeen Back Pain Scale
Confirmatory (the
baseline measurement
of pain)
Physical
functioning
e.g., Oswestry Disability
Index, Roland Morris
Disability Questionnaire
Confirmatory (the
baseline measurement
of physical functioning)
Secondary outcomes
Recovery Global assessment
Return-to-
work
e.g., numbers of days of
work absenteeism, number
of participants that
returned to work
Quality of life Short Form-36 Item Health
Survey, EuroQol (EQ5D)
Confirmatory (the
baseline measurement
of quality of life)
Satisfaction Satisfaction with treatment
Satisfaction with outcome
Reduction in
frequency of
analgesic use
Table 2 Overview of prognostic factors extracted for IDP
analyses and the role of the variable in moderator analysis
Individual subject
characteristics
Prognostic factors
Age Confirmatory
Gender Exploratory
Height, weight, body mass index Exploratory
Ethnicity/race Exploratory
Lifestyle factors
Participation in sports activities or
physical fitness level
Exploratory
Smoking Exploratory
Alcohol use Exploratory
Sociodemographic characteristics
Marital status Exploratory
Level of education Exploratory
Income Exploratory
Employment status Exploratory
Nature and severity of the low back pain
Duration of the low back pain Confirmatory
Non-specific Exploratory
Radiation Exploratory
Previous low back pain treatment
received
Exploratory
Comorbidities, e.g., diabetes, heart disease
Presence of comorbidities Exploratory
Number of comorbidities Exploratory
Category of comorbidities Exploratory
Type of
treatment
Manipulation, mobilization,
combination
Psychosocial
factors
e.g., Back Depression Inventory, Fear
Avoidance Beliefs Questionnaire
Confirmatory
Treatment
preference/
expectation
e.g., preference for treatment,
previous experience with treatment,
expectation to final improvement,
self-efficacy scale/beliefs
Confirmatory
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interventions for treatment of chronic LBP. Determin-
ation of what interventions were considered ineffective
and effective was based upon the literature and our in-
terpretation of those results [4].
Types of outcome measures
Primary outcomes
 Pain expressed on a self-reported scale (e.g., visual
analog scale (VAS), numerical rating scale (NRS))
 Functional status expressed on a back-pain specific
scale (e.g., Roland-Morris Disability Questionnaire,
Oswestry Disability Index)
Secondary outcomes
 Health-related quality of life (e.g., SF-36 (as mea-
sured by the general health subscale), EuroQol, gen-
eral health (e.g., as measured on a VAS scale) or
similarly validated index)
 Return-to-work (self-reported or registry-based)
 Global improvement or perceived recovery
(recovered is defined as the number of patients
reported to be recovered or nearly recovered)
 Self-reported satisfaction with treatment
 Reduction in frequency of analgesic use (self-
reported or registry-based)
Search methods for identification of new studies
RCTs that were identified and described in the Cochrane
Review on non-specific chronic LBP [4] will be used and
complemented by additional RCTs which have been
published later than the census date for the Cochrane
Review.
All the steps, including the selection of studies and
evaluation of the risk of bias will be conducted by two
independent reviewers (SMR, AdeZ). Both review au-
thors have a background in chiropractic and are prac-
ticing clinicians, but also have training in epidemiology.
SMR is the principal author of the Cochrane Review of
SMT for chronic LBP [4], which will ensure consistency
in the evaluation of the risk of bias. When necessary, a
third reviewer (RO) will be contacted.
Electronic searches
The search strategy includes a computerized search of
electronic databases since the last Cochrane Review up-
date (June 2009 to December 2014) (Additional file 2):
 CENTRAL from The Cochrane Library 2009, issue 2
to December 2014
 MEDLINE from June 2009 to December 2014
 Embase from June 2009 to December 2014
 CINAHL from June 2009 to December 2014
 PEDro from June 2009 to December 2014
 Index to Chiropractic Literature from June 2009 to
December 2014
The search will be in line with the recommendations
of the Cochrane Back and Neck (CBN: formerly the
Cochrane Back Review Group) which was used in
Cochrane Review on non-specific chronic LBP. We will
update the search mid-2016.
We will conduct citation searches of the previous re-
view publications and screen cited references of other
recent SMT systematic reviews [22, 23]. Also, we will
identify abstracts which have been published after 2009
for which no full article has been published and search
the trial register (ClinicalTrials.gov) for unpublished tri-
als. Finally, we will contact content experts for additional
trials.
Data extraction of the additional RCTs
A standard protocol will be followed for study selection
and data abstraction. Potentially relevant studies will be
obtained in full text and independently assessed for in-
clusion. There will be no language restrictions.
We will extract data on study characteristics (e.g.,
country where the study was conducted, recruitment
method, source of funding, patient characteristics (e.g.,
number of participants, age, gender), description of the
experimental and control interventions, co-
interventions, duration of follow-up, types of outcomes
assessed, and the authors’ reported results and
conclusions).
We will extract outcome data for all time periods re-
ported in the original studies. We will define sufficiently
similar categories of follow-up using the Cochrane Re-
view as a guidance, which defined the following categor-
ies: 1, 3, 6, 12, and more than 12 months [4]. Outcomes
will be categorized according to the time closest to these
intervals.
Assessment of risk of bias in included studies
We will use the assessment of the risk of bias already
completed for the studies in the Cochrane Review. Risk
of bias for each published study after June 2009 will be
assessed using criteria recommended by the CBN [24].
These criteria are standard for evaluating effectiveness of
interventions for LBP. The criteria will be scored as
“yes,” “no,” or “unclear” and presented in the Risk of Bias
table. Any disagreement will be resolved by discussion
and the same independent third reviewer can be con-
tacted if necessary.
Collection of IPD
The original data will be sought from the authors of all
studies fulfilling the inclusion criteria. The contact
de Zoete et al. Systematic Reviews  (2017) 6:21 Page 5 of 11
information of the authors of identified trials will be
found in the publication, on PubMed or the internet.
The authors will be sent an information about our IPD
analysis by e-mail and will be asked to share their IPD
along with their variable codebook. If no codebook is
present, copies of their original data collection forms will
be requested. If there is no response from the contact
author other study authors will be contacted. Two re-
minders will be sent to all authors.
Previous contact by SMR for his Cochrane Review re-
sulted in prompt assistance from most authors, particu-
larly from recently published trials. Communication to
date has resulted in 17 authors willing to participate.
Several authors have published more than one trial.
Each participating study author will be sent an IPD
policy form which contains information regarding data
ownership, data confidentiality, data access and use,
publication rules, and (co-) authorship. Authors will be
asked to fill in an IPD data request form (this document
asks for verification of eligibility criteria, the willingness
to share information, and to provide contact details).
Authors are required to sign the IPD Data Sharing
Agreement (a contract between the author and the VU
University describing the condition regarding data as
stated in the IPD policy). Finally, the author receives an
IPD Data Transfer Protocol (containing information on
how to send the data). (see additional file 3)
Raw de-identified data will preferably be sent to the
VU University Amsterdam by e-mail after the data are
encrypted by a program such as Axcrypt; however, the
methods for receiving raw data may vary depending on
the security concerns from the participating institutions.
Databases in all formats will be accepted. After the data
have been received, they will be stored on a secure insti-
tutional server.
Data will be sought for all participants (this includes
those who were excluded from the original analysis) at
all time points and will be grouped later for analyses.
We will collect and extract data in the domains de-
scribed in the Tables 1 and 2.
Preparing data for analyses
We will compare the original data with the published
data to check for completeness and improbable values,
and where possible, we will solve the discrepancies be-
tween our results and those presented in the original
data, with the original study author.
All variables will be harmonized in a data
harmonization platform (DHP) developed for the PO-
LARIS study [25]. Briefly, this DHP support us with the
steps of importing and harmonizing the original studies
with a master data dictionary and exporting the selected
variables and studies into one harmonized SPSS dataset
for the proposed statistical analyses (see Fig. 1). Our
master data dictionary (see additional file 4) describes
the data as extensively as possible allowing us to keep
the original variable. Consequently, this leads to a gain
in information for the analyses compared to aggregate
data. For example, some studies may only report particu-
lar outcomes of the Oswestry Disability Index in their
publications. In contrast, we can include all separate
items from the Oswestry Disability Index in addition to
the total score as well as including various measures for
pain.
The DHP is used to rename, label, and integrate the
variables for each included study with the master data
dictionary in a consistent manner. If in doubt, we will
contact primary study authors for clarification and/or
discuss within the steering committee consisting of all
authors.
Whenever possible, we will maintain data for continu-
ous measurement of variables. If data on a variable of
interest are not available in the dataset, we will attempt
to extract this information based on other data in the set
(e.g., sick leave variable is missing, but there is a variable
on disability pension or workers compensation). We will
address subject-level missing data on variables and out-
comes if necessary. For example, missing baseline vari-
able data will be handled using multiple imputation
techniques, under a missing-at-random assumption, so
as to avoid excluding patients from the analysis and to
ensure that the baseline balance between treatment
groups is maintained.
Data analysis
Overall treatment effect of SMT in adults with LBP
We will perform IPD meta-analyses to assess the treat-
ment effect of SMT for primary and secondary outcomes
in adults with chronic LBP. The primary outcomes are
pain- and back pain-related disability. The secondary
outcomes of interest include perceived recovery, return-
to-work or absenteeism, health-related quality of life,
satisfaction with treatment, and reduction in frequency
of analgesic use. In the first instance, we will pool data
of different scales measuring the same construct. If,
however, different scales measuring the same construct
cannot be combined because the scales differ, the choice
of the analysis will be determined by where the majority
of the data lie.
If more than one measurement scale for a domain
e.g., pain within one study has been collected, we will
use the most common scale used within trials in the
IPD database. If in a domain, different scales measure
different constructs as in the case of functional status
(e.g., Oswestry Disability Index, Roland Morris Dis-
ability Questionnaire) then this construct will be ex-
amined separately.
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Comparison therapies will be combined into the fol-
lowing main clusters: (1) SMT versus inert interventions,
(2) SMT versus sham SMT, (3) SMT versus all other in-
terventions, and (4) SMT in addition to any intervention
versus that intervention alone.
In the group, SMT versus all other interventions, we
will look at the clinical homogeneity of the comparison.
This may result in another classification, for example
SMT versus exercise.
Our primary analyses will consist of one-stage IPD
meta-analyses, taking into account within study cluster-
ing of study effects. These models will take the form of
the following:
γ ik ¼ αi þ βixik þ θizik þ eik
θi ¼ θ þ ui
ui∼N 0; τ2
 
eik∼N 0; σ2
 
where γik refers to the estimated continuous outcome
for the kth person in the ith study (for binary outcomes
γik refers to the logit of the outcome), αi represents
study-specific intercepts, βi represents the adjustment
for the baseline outcome, ui is a random effect indicating
the treatment effect in the ith trial, and θi is normally
distributed around a pooled treatment effect with
between-study variance τ2. σ2 is the residual variance of
the responses in trial i after accounting for the treatment
effect.
In order to compare our results with the outcomes of
the original studies and as a sensitivity analysis to our
one-stage analyses, we will also conduct two-stage ana-
lyses which take the following form:
Stage 1: Model for each trial separately
γ ik ¼ αi þ βixik þ θizik þ eik
eik∼N 0; σ2
 
Stage 2
The estimates of each trial θ^ i
 
and the estimates of
the variance V for each trial V θ^ i
 
are subsequently
pooled in a random effects model.
θ^ i ¼ θi þ εi
εieN 0; V θ^ i
  
θi ¼ θ þ ui
ui∼N 0; τ2
 
The pooled treatment effect of SMT will be estimated
according to a mean difference (for continuous out-
comes) or an odds ratio (for binary outcomes) and their
95% CIs, based on the intention-to-treat (ITT) principle.
Fig. 1 Data harmonization process. Reprinted with permission: Buffart LM, Kalter J, Chinapaw MJ, Heymans MW, Aaronson NK, Courneya KS, et al. Rationale and
design for meta-analyses of individual patient data of randomized controlled trials that evaluate the effect of physical activity and psychosocial interventions on
health-related quality of life in cancer survivors. Predicting OptimaL cAncer RehabIlitation and Supportive care (POLARIS): Systematic reviews. 2013;2:75
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We recognize that variables may not be reported in all
trials, and so, some analyses may need to be restricted to
the subset of trials providing each variable of interest.
Possible moderation of baseline characteristics on
treatment response
We will examine treatment effect modification at the pa-
tient level, to assess whether individual patient charac-
teristics measured at baseline are associated with
treatment response.
Candidate moderators of treatment response have
been identified (see Tables 1 and 2). The selection of
these moderators was based on a specific rationale e.g.,
understanding behavioral and sociocultural mechanisms
by which response is modified or from prognostic re-
search (treatment effect modification studies or prognos-
tic factor research) [20, 26, 27]. The interactions
between the intervention and potential moderators will
be examined.
Moderator analysis can be classified into confirmatory
or exploratory. Moderators in confirmatory analyses are
those related to specific theory or evidence, while mod-
erators in exploratory analyses relate to moderators for
which no empirical evidence exists or which a specific
mechanism is lacking. These will be explored in order to
inform future trials [28]. In Tables 1 and 2, we have indi-
cated which analyses are confirmatory and which are ex-
ploratory [20, 26–32].
For the moderator analyses, we will extend the one-
step IPD meta-analysis framework described above to in-
clude the potential effect modifiers and interaction terms
between treatment and each variable. Potential modera-
tors will be analyzed one by one in the following model.
γ ik ¼ αi þ βixik þ θizik þ μiωik þ γwzik ωik−ωið Þ þ eik
θi ¼ θ þ γAzi þ ui
ui∼N 0; τ2
 
eik∼N 0; σ2
 
where μi represents the patient-level covariate (fixed
effect of the potential moderator), γw explains the
patient-level variation in treatment response, γA repre-
sents the across trial interaction, and τ2 represents the
unexplained between-study variance.
If the interaction terms are statistically significant, we
will present treatment effects for subgroups with the
95% confidence interval of size of the interaction terms.
If convergence is achieved, we will investigate multiple
moderators in the same analysis.We will discuss if those
variables are clinically important effect modifiers in a
consensus meeting. We will use the current knowledge
on minimal clinically important changes within
individual patients as guidance, because there is no
current literature on minimal clinically important differ-
ences between groups. The current literature states that
as any improvement in score ≥30% of its baseline value,
with a minimum value of 20-point (/100) improvement
in pain and 10-point (/100) improvement in functioning
is clinically important [33, 34].
Effects of characteristics of the intervention (e.g.,
manipulation/mobilization) on treatment response
We will use the one-stage IPD meta-analysis framework
described above to assess the treatment effect of each
type of SMT technique for primary in adults with
chronic LBP, by stratifying the analyses by type of SMT.
Type of SMT technique groups will be manipulation,
mobilization, or mixed where both techniques were used
and will be compared to the same comparison groups as
for the overall effect. These analyses will be exploratory
as the mechanisms of how manipulation/mobilization
works are not yet fully understood.
Where possible, for each analysis, we will compare the
effect of SMT considering the dose (number of SMT
treatments). We will recognize that this is a study-level
comparison, and thus subject to potential study-level
confounding
Expected mediators of treatment effects
Mediators are causal links between the intervention and
the outcome and identify how an intervention might
achieve its effects. For example, physical functioning
may mediate the association between SMT and return-
to-work. Potential mediators of the intervention effect
on the outcomes will be explored using the potential
outcome framework [35–37].
All mediator analyses will be exploratory as there is lit-
tle information in the literature on mediators that influ-
ence SMT for chronic LBP. Mediators in the treatment
of LBP that have been identified are mostly cognitive
and psychological mediators like sleep, fear beliefs, self-
efficacy, stress, and satisfaction [38]. The effects of these
mediators will be explored as well as the mediator pain
for physical function and return-to-work.
Sensitivity analyses
In order to determine the robustness of the main analyses,
sensitivity analyses will be conducted to assess the impact
of our review methods, decisions, and definitions.
An analysis will be carried out to assess the effects of
imputing missing data by comparing several imputation
methods [17, 39, 40]. We will perform sensitivity ana-
lyses in which data from persons with missing baseline
values will be imputed following the two-stage model
proposed by Burgess et al [41]. In this model, data are
first imputed within studies and treatment effects are
de Zoete et al. Systematic Reviews  (2017) 6:21 Page 8 of 11
derived using Rubin’s Rules and subsequently, these ef-
fect estimates are pooled by inverse variance weighting
[41]. In addition, inclusion of only studies with a low risk
of bias, where studies with a low risk of bias will be de-
fined as those that fulfill six or more of the 12-criteria
items, will be performed to assess the impact of studies
of lower methodological quality on the findings. Besides
dividing the studies in a low and high risk of bias, we
will compare studies with difference in the criteria of the
risk of bias (for example, concealment versus no con-
cealment of treatment allocation).
Lastly, additional sensitivity analyses will be performed
related to the definitions of sufficiently similar measures
for patient-level variables and the definitions of follow-
up time points. Not all studies have the same follow-up
evaluations of the outcomes. Data might either be mea-
sured at different time points or come from different
outcome measures. In addition, in many of the included
studies, the potential moderators or moderators might
not be available. This will limit us in the possible
analyses.
Publication policy
A Back Pain IPD Consortium was formed consisting of
a steering committee, an international advisory commit-
tee and collaborators. The steering committee will be re-
sponsible for the daily management of the study and its
coordination. The international advisory committee con-
sists of experts in the field of LBP and SMT and there-
fore, is in the position to give specific advice on SMT as
it relates to the field of LBP. Collaborators are the
principle investigators of a RCT. We will invite new col-
laborators as new eligible studies become available.
A meeting for collaborators and international advisory
committee will be held to update the members on the
progress of the study and to discuss the challenges
encountered.
The primary publication of the results of this review
will be prepared by the steering committee. These re-
sults will be circulated to the members of the Back Pain
IPD Consortium for a critical comment. The collabora-
tors and international advisory committee members will
be listed as the Back Pain IPD group, and all participat-
ing investigators contributing to this project will be
listed at the end of each publication. All co-authors need
to comply with the criteria of the Vancouver Protocol
for co-authorship.
In addition to the present analysis, we intend to estab-
lish a repository for future use of these data.
Discussion
In this project, we will perform an IPD meta-analysis on
SMT for chronic LBP. We aim to examine the main ef-
fects of SMT on primary and secondary outcomes, as
well as to analyze possible moderator and mediator ef-
fects. In addition, we will examine whether there are dif-
ferences in outcome based upon different types of SMT.
The results of our analyses will be compared to the re-
sults from the previously conducted aggregate meta-
analyses [4]. Studies have shown that IPD meta-analysis
due to the increased sample size, consistent presentation
of data, and additional analysis to explore heterogeneity
can be more reliable and valid than aggregate data meta-
analysis [19], although this difference might also be at-
tributed to the number of studies that can be used or
the amount of data that can be utilized.
Therefore, this project may identify important gaps in
our knowledge with respect to prognostic factors of treat-
ment effects. Besides that, this project will help to improve
quality, design, and reporting of LBP trials with respect to
collection of information on prognostic factors relevant to
the identification of treatment subgroups .
Finally, one of the loftier goals of this IPD study is to
establish an international collaborative group on IPD in
the field of LBP. This will provide in the future a unique
opportunity to compare the effect of different treatment
modalities and to investigate gaps in the literature, in-
cluding comparison of the results of traditional meta-
analysis using standard aggregate-level approaches,
multi-treatment meta-regression, and IPD.
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